{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:19:32Z","timestamp":1761506372269,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cllc.2023.01.001","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T02:20:14Z","timestamp":1674267614000},"page":"244-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Colton","family":"Ladbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Abuali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6205-5969","authenticated-orcid":false,"given":"Arya","family":"Amini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.01.001_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2023.01.001_bib0002","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2023.01.001_bib0003","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from apopulation-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2023.01.001_bib0004","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.01.001_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0006","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.athoracsur.2014.01.052","article-title":"A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer","volume":"98","author":"Endo","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2023.01.001_bib0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ijrobp.2022.08.040","article-title":"A comparison of two disease burden assessment methods (3D volume versus the number of lesions) for prognostication of survival in metastatic melanoma: implications for the characterization of oligometastatic disease","volume":"114","author":"Kim","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2023.01.001_bib0009","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.oraloncology.2012.07.016","article-title":"The role of 18F-FDG PET\/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma","volume":"49","author":"Chan","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0010","first-page":"120","article-title":"Prognostic value of FDG PET\/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients","volume":"6","author":"Marinelli","year":"2016","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2023.01.001_bib0011","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2214\/AJR.14.13906","article-title":"Whole-body metabolic tumor volume, as determined by 18F-FDG PET\/CT, as a prognostic factor of outcome for patients with breast cancer who have distant metastasis","volume":"205","author":"Son","year":"2015","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0012","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2967\/jnumed.113.131847","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET\/CT in patients with pancreatic cancer","volume":"55","author":"Lee","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cllc.2023.01.001_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.cllc.2023.01.001_bib0014","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.clinthera.2015.07.014","article-title":"Role of gross tumor volume in the prognosis of non\u2013small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis","volume":"37","author":"Yu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.cllc.2023.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jtho.2018.06.007","article-title":"Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy","volume":"13","author":"Shiue","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0360-3016(01)01772-2","article-title":"Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma","volume":"52","author":"Bradley","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2023.01.001_bib0017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00066-017-1221-y","article-title":"Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer","volume":"194","author":"K\u00e4smann","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2005.11.008","article-title":"Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy","volume":"52","author":"Stinchcombe","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.01.001_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2007.06.034","article-title":"Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the radiation therapy oncology group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non\u2013small-cell lung cancer","volume":"70","author":"Werner-Wasik","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2023.01.001_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2023.01.001_bib0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JTO.0b013e31815e6d6b","volume":"3","author":"Berghmans","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0022","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3109\/0284186X.2010.550933","article-title":"Is there a common SUV threshold in oncological FDG PET\/CT, at least for some common indications? A retrospective study","volume":"50","author":"Nguyen","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0023","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2012.47.5947","article-title":"Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non\u2013small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668\/RTOG 0235 trial","volume":"31","author":"Machtay","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0024","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0360-3016(01)01988-5","article-title":"Positron emission tomography after three-dimensional conformal radiation therapy for non-small cell lung cancer","volume":"51","author":"Rosenzweig","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2023.01.001_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/ijnm.IJNM_134_20","article-title":"Optimal standardized uptake value threshold for auto contouring of gross tumor volume using positron emission tomography\/computed tomography in patients with operable nonsmall-cell lung cancer: Comparison with pathological tumor size","volume":"36","author":"Tibdewal","year":"2021","journal-title":"Indian J Nucl Med IJNM Off J Soc Nucl Med India"},{"key":"10.1016\/j.cllc.2023.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2967\/jnumed.107.044362","article-title":"18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?","volume":"48","author":"Hellwig","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cllc.2023.01.001_bib0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.radonc.2021.04.019","article-title":"A deep learning-based auto-segmentation system for organs-at-risk on whole-body computed tomography images for radiation therapy","volume":"160","author":"Chen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2023.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40336-022-00482-z","article-title":"Deep learning-based auto-segmentation of lung tumor PET\/CT scans: a systematic review","volume":"10","author":"Kao","year":"2022","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.cllc.2023.01.001_bib0029","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/mp.12124","article-title":"Classification and evaluation strategies of auto-segmentation approaches for PET: report of AAPM task group No. 211","volume":"44","author":"Hatt","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.cllc.2023.01.001_bib0030","doi-asserted-by":"crossref","first-page":"pkab012","DOI":"10.1093\/jncics\/pkab012","article-title":"Response rate and survival at key timepoints with PD-1 blockade vs chemotherapy in PD-L1 subgroups: meta-analysis of metastatic NSCLC trials","volume":"5","author":"Man","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.cllc.2023.01.001_bib0031","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00262-020-02810-6","article-title":"A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC","volume":"70","author":"Del Re","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2023.01.001_bib0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall'Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:46Z","timestamp":1761506086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1525730423000037"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.01.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}